Rocio Montejano

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 64 publications

Metformin and Weight Changes in Non-diabetic Older People With HIV (METFORAGING): A Double-Blind, Randomized, Placebo-Controlled, Pilot Trial.

Metformin and Weight Changes in Non-diabetic Older People With HIV (METFORAGING): A Double-Blind, Randomized, Placebo-Controlled, Pilot Trial.

Journal: Open forum infectious diseases

Published: June 22, 2026

DNA methylation-based estimator of blood telomere length (DNAmTL) outperforms qPCR-based telomere length in reflecting clinical and sociodemographic factors in people with HIV infection.

DNA methylation-based estimator of blood telomere length (DNAmTL) outperforms qPCR-based telomere length in reflecting clinical and sociodemographic factors in people with HIV infection.

Journal: Clinical epigenetics

Published: February 16, 2026

Prevalence and Mortality of Tuberculosis at HIV Diagnosis in Spain, 2004-2024.

Prevalence and Mortality of Tuberculosis at HIV Diagnosis in Spain, 2004-2024.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: February 03, 2026

Prevalence and mortality of tuberculosis at HIV diagnosis in Spain, 2004-2024.

Prevalence and mortality of tuberculosis at HIV diagnosis in Spain, 2004-2024.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: February 03, 2026

Metformin and epigenetic age in non-diabetic older people with HIV in Madrid (METFORAGING): a double-blind, randomised, placebo-controlled, pilot trial.

Metformin and epigenetic age in non-diabetic older people with HIV in Madrid (METFORAGING): a double-blind, randomised, placebo-controlled, pilot trial.

Journal: EClinicalMedicine

Published: November 26, 2025

Hepatitis B reactivation in people living with HIV and isolated anti-HBc receiving tenofovir-sparing dual antiretroviral therapy.

Hepatitis B reactivation in people living with HIV and isolated anti-HBc receiving tenofovir-sparing dual antiretroviral therapy.

Journal: HIV medicine

Published: October 31, 2025

Impact of Proviral-DNA M184V/I on 96-Week Outcomes of DTG/3TC Maintenance Therapy: Results From the VOLVER Clinical Trial.

Impact of Proviral-DNA M184V/I on 96-Week Outcomes of DTG/3TC Maintenance Therapy: Results From the VOLVER Clinical Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: October 19, 2025

Prognostic value of blood epigenetic biomarkers of aging in persons with well controlled HIV infection.

Prognostic value of blood epigenetic biomarkers of aging in persons with well controlled HIV infection.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: June 13, 2025

Prognostic Value of Blood Epigenetic Biomarkers of Aging in Persons With Well-Controlled HIV-1 Infection.

Prognostic Value of Blood Epigenetic Biomarkers of Aging in Persons With Well-Controlled HIV-1 Infection.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: June 13, 2025

Preparing for the Next Physician's Visit: Usability and Validity of a Mobile Health App for People Living with HIV.

Preparing for the Next Physician's Visit: Usability and Validity of a Mobile Health App for People Living with HIV.

Journal: AIDS and behavior

Published: April 29, 2025

Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.

Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.

Journal: The lancet. HIV

Published: February 18, 2025

Dolutegravir/Lamivudine for Maintenance of Virological Suppression in Persons With Historical Suspected or Confirmed Resistance to Lamivudine: Week 48 Results of a Single-Arm, Open-Label, Multicenter, Phase IIa Clinical Trial.

Dolutegravir/Lamivudine for Maintenance of Virological Suppression in Persons With Historical Suspected or Confirmed Resistance to Lamivudine: Week 48 Results of a Single-Arm, Open-Label, Multicenter, Phase IIa Clinical Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: November 12, 2024

Showing 1-12 of 64

Last Updated: 09/26/2026